How do doctors want to engage with pharma on new products?

With more than 80 per cent of European doctors saying they want to stay abreast of new developments about pharmaceutical products, it is important to understand how they wish to receive this information.

A survey by M3 Global Research of over 1,800 doctors from the top five EU countries and beyond has consolidated their thinking and finds that they value pharma's contribution. In fact, 72 per cent say the industry's delivery of new medicines will be the main factor helping to improve the outlook for their patients over the next three years.

Download the White Paper now to discover how doctors are accessing the latest developments about medicines and their preferred ways of receiving promotional material.

http://www.pharmaphorum.com/media/com_content/whitepaper/3146_how%20do%20doctors%20want%20to%20engage%20with%20pharma%20on%20new%20products11dec14.pdf

Φαρμακευτικό Μάρκετινγκ: Θεωρία, Πρακτική, Δεοντολογία

The ultimate guide for Pharma Marketing Champions

Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…

http://www.stamoulis.gr/ViewShopProduct.aspx?ProductId=402023

Drug Launch Watch List 2015 by Frost & Sullivan

Oncology, cardiovascular, autoimmune/anti-inflammatories, and infectious diseases will be the top areas of investments in 2015, according to Frost & Sullivan. Pharma companies will also be keen to invest in in-vitro diagnostics such as biomarkers; molecular, tissue, companion diagnostics; predisposition disease; and predictive testing, added the company's Life Sciences Global Program Director, Jennifer Lazar.

Frost & Sullivan has released its "Drug Launch and Phase 3 Trial Watch List for Top Therapy Areas for 2015". It includes: 

• Puma Biotechnology’s tyrosine kinase inhibitor, neratinib, for breast cancer adjuvant therapy.

• Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, nivolumab, for previously treated advanced melanoma patients. 

• Novartis’ selective IL-17A inhibitor, secukinumab, for the treatment of plaque psoriasis. 

• Novartis’ angiotensin receptor neprilysin inhibitor (ARNi), LCZ696, for the treatment of heart failure.

• AbbVie’s ABT-450/ritonavir co-formulated with ombitasvir (ABT-267), and dasabuvir (ABT-333) with or without ribavirin for the treatment of hepatitis C.

• GlaxoSmithKline’s RTS,S vaccine is expected to be the first malaria vaccine in the market.

• Sanofi Pasteur's Dengue Vaccine. 

In addition to new molecular entity product launches, Frost & Sullivan reports that there are "abundant opportunities for generic and biosimilar drugs due to the patent expiry of several blockbuster drugs in 2014 and 2015". Some of those include: 

• Otsuka Pharmaceutical’s Abilify (anti-psychotic) 
• Teva Pharmaceutical’s Copaxone (relapse-remitting multiple sclerosis) 
• Novartis’ Gleevec (chronic myeloid leukemia) 
• Forest Laboratories’ Namenda (Alzheimer’s disease) 
• Pfizer’s Zyvox (anti-viral) and, 
• GlaxoSmithKline’s Avodart (benign prostatic hyperplasia) 

 

Φαρμακευτικό Μάρκετινγκ: Θεωρία, Πρακτική, Δεοντολογία

The ultimate guide for Pharma Marketing Champions

Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…

http://www.stamoulis.gr/ViewShopProduct.aspx?ProductId=402023